Sphera Management Technology Funds Ltd acquired a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 40,000 shares of the company's stock, valued at approximately $881,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Juncture Wealth Strategies LLC increased its holdings in Cellebrite DI by 0.8% in the fourth quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company's stock worth $1,322,000 after purchasing an additional 505 shares in the last quarter. Bosun Asset Management LLC raised its holdings in Cellebrite DI by 1.4% during the fourth quarter. Bosun Asset Management LLC now owns 43,307 shares of the company's stock worth $954,000 after buying an additional 584 shares during the last quarter. TD Waterhouse Canada Inc. lifted its position in Cellebrite DI by 1.8% in the 4th quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company's stock valued at $1,046,000 after acquiring an additional 859 shares in the last quarter. Strategic Advisors LLC boosted its position in shares of Cellebrite DI by 3.4% during the fourth quarter. Strategic Advisors LLC now owns 29,082 shares of the company's stock valued at $641,000 after buying an additional 950 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC grew its stake in shares of Cellebrite DI by 12.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company's stock worth $299,000 after acquiring an additional 1,463 shares in the last quarter. Institutional investors own 45.88% of the company's stock.
Analysts Set New Price Targets
CLBT has been the subject of several recent research reports. Needham & Company LLC decreased their price objective on Cellebrite DI from $28.00 to $24.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Lake Street Capital upped their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. dropped their price target on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday, May 12th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $22.43.
Check Out Our Latest Report on CLBT
Cellebrite DI Trading Up 0.8%
CLBT opened at $17.41 on Monday. Cellebrite DI Ltd. has a 12-month low of $10.25 and a 12-month high of $26.30. The company's 50 day moving average is $19.02 and its 200 day moving average is $20.26. The company has a market cap of $4.17 billion, a price-to-earnings ratio of -12.53, a PEG ratio of 4.27 and a beta of 1.44.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.09 by $0.01. The business had revenue of $107.55 million during the quarter, compared to the consensus estimate of $109.36 million. Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. The business's revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.08 EPS. As a group, analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
